Biotech Co.* |
Pharma Co. (Country) |
Product |
Terms/Details (Date) |
| | |||
Celltech Group plc (UK; NYSE:CLL; LSE:CCH) |
Lonza Biotec (division of Lonza Group Ltd.; Switzerland) |
PEGylated antibody fragment-based drugs |
Lonza Biotec will manufacture PEGylated antibody fragment-based drugs for Celltech at its microbial production facility (7/14) |
|
|
|
|
Columbia Laboratories Inc. (AMEX:COB) |
Mipharm SpA (Italy) |
Striant |
Mipharm will market Columbia's Striant (testosterone buccal system) mucoadhesive in Italy; it also will distribute and sell the product; Columbia will receive payments of $1.4M, including the reimbursement of $350,000 in development costs, as well as milestone and royalty payments (6/9) |
|
|
||
Corixa Corp. (CRXA) |
GlaxoSmithKline plc (UK) |
Bexxar |
GlaxoSmithKline will be responsible for registration, marketing and sales of Bexxar therapy in Canada; Corixa will manufacture and supply the product to Glaxo, which will pay up-front license fees, milestone payments and royalties on all future Canadian sales (5/29) |
|
|
|
|
Corixa Corp. (CRXA) |
MDS Nordion (Canada) |
Bexxar |
Seven-year manufacturing agreement in which MDS Nordion will continue to radio-label the antibody in Bexxar (6/24) |
|
|
||
Crimson Pharmaceutical |
Octamer Inc. |
Agreement for Crimson to license three drug candidates from Octamer |
The compounds are being investigated to treat a variety of diseases including cancer, AIDS and acute inflammatory conditions such as stroke; Crimson obtained exclusive rights to develop and market the licensed compounds in China, Korea, Hong Kong, Taiwan, Singapore and other areas in Southeast Asia (7/21) |
|
|||
CytoGenix Inc. (OTC BB:CYGX) |
Phanuel Pursuits Ltd. (British Virgin Islands) |
Anti-herpes topical cream |
Agreement in which CytoGenix granted Phanuel an option to exclusively license manufacturing and distribution of its anti-herpes topical cream in China (7/17) |
|
|||
ICOS |
Eli Lilly and Co. |
Two undisclosed clinical candidates being developed by Lilly |
The companies entered an agreement in which ICOS will manufacture the candidates (6/6) |
|
|
|
|
GeneMedix plc |
Penang Development Corp. (Malaysia) |
Agreement to set up a company in Penang for the development, manufacture and commercialization of human insulin |
GeneMedix would outlicense its existing insulin knowledge to a newly formed Malaysian company and help build manufacturing facilities; the investment is anticipated to be $34M in development loans, grants and an issue of equity in the newly formed company to local investors; GeneMedix will receive an up-front payment and potential milestone payments and royalties in return for its outlicensing (6/13) |
|
|
||
Pozen Inc. |
Nycomed Danmark ApS (Denmark) |
MT 100 |
Agreement for Pozen to license MT 100 to Nycomed for Nordic sales rights; Nycomed will sell the product in Denmark, Sweden, Norway and Finland; Nycomed will pay Pozen a $500,000 up-front fee, as well as milestone payments totaling $1M, and a double-digit royalty on sales (7/1) |
|
|
||
SCIL Biomedicals GmbH* (Germany; subsidiary of SCIL Technology Holding GmbH) |
Laxdale Ltd. (Scotland) and Scarista Ltd. (UK) |
Lyxia |
SCIL gained sales and marketing rights in Germany, France, Austria, Benelux, Switzerland, Poland, Hungary, the Czech Republic and Slovakia (6/13) |
|
|
||
Synthetic Blood International Inc. (OTC BB:SYBD) |
PrimaPharm Inc. |
Oxycyte |
PrimaPharm will manufacture Oxycyte, a perfluorocarbon blood subsitute, for upcoming clinical trials; it could be useful in treating stroke, heart attack and cancer (7/23) |
|
|||
Viragen Inc. (AMEX:VRA) and Viragen International Inc. (OTC BB:VGNI) |
Arriani Pharmaceuticals SA (Greece) |
Natural human alpha interferon, Multiferon |
Exclusive distribution agreement with Arriani distributing Multiferon in Greece and designated Balkan countries; agreement is worth $9.5M in sales revenues over five years (5/27) |
|
|||
Viragen Inc. (AMEX:VRA) and Viragen International Inc. (OTC BB:VGNI) |
CJ Pharma (division of CJ Corp.; South Korea) and subsidiary CJ Hong Kong Ltd. |
Natural interferon |
CJ Pharma and CJ Hong Kong will exclusively distribute natural interferon in Hong Kong (5/22) |
|
|
||
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
To read more on related topics, click on one of the words below.